SMARCA1: A Potential Drug Target for Various Diseases (G6594)

Target Name: SMARCA1

NCBI ID: G6594

SMARCA1

SMARCA1: A Potential Drug Target for Various Diseases

SMARCA1 (SNF2L) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein encoded by SMARCA1 is a key regulator of the skeleton and has been shown to play a role in the development and progression of various diseases.

SMARCA1 was first identified in 2006 using genomic screening techniques as a potential gene that was involved in the regulation of bone development and homeostasis. Since then, several studies have confirmed that SMARCA1 is indeed a non-coding RNA (ncRNA) that is expressed in a variety of tissues and cells, including skeletal muscles, neurons, and immune cells.

One of the key functions of SMARCA1 is its role in regulating the activity of the protein SNF2, which is a key regulator of the immune response and has been implicated in the development of autoimmune diseases. Studies have shown that SMARCA1 can physically interact with SNF2 and that the activity of SNF2 can be regulated by SMARCA1.

Another function of SMARCA1 is its role in the regulation of cell proliferation. Studies have shown that SMARCA1 can inhibit the activity of the oncogene transforming growth factor-beta (TGF-beta), which is a key regulator of cell proliferation and has been implicated in the development of cancer.

SMARCA1 has also been shown to play a role in the regulation of the nervous system. Studies have shown that SMARCA1 can interact with the protein brain-derived neurotrophic factor (BDNF), which is a protein that promotes the survival and proliferation of neurons and is often impaired in neurodegenerative diseases.

In addition to its functions in regulating SNF2 and cell proliferation, SMARCA1 has also been shown to play a role in the regulation of the immune system. Studies have shown that SMARCA1 can interact with the protein IRAK4, which is involved in the regulation of inflammation and has been implicated in the development of autoimmune diseases.

SMARCA1 has also been shown to play a role in the regulation of cellular adhesion. Studies have shown that SMARCA1 can interact with the protein E-cadherin, which is involved in the regulation of cell-cell adhesion and has been implicated in the development of various diseases, including cancer.

In conclusion, SMARCA1 is a gene that has been shown to play a role in the regulation of various physiological processes in the cell. Its functions in regulating SNF2, cell proliferation, nervous system, and immune system make it a potential drug target or biomarker for the treatment of various diseases. Further research is needed to fully understand the role of SMARCA1 in disease development and to develop effective treatments.

Protein Name: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 1

Functions: Catalytically inactive when either DNA or nucleosomes are the substrate and does not possess chromatin-remodeling activity (PubMed:15310751, PubMed:28801535). Acts as a negative regulator of chromatin remodelers by generating inactive complexes (PubMed:15310751)

The "SMARCA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMARCA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets